<DOC>
	<DOCNO>NCT02627274</DOCNO>
	<brief_summary>This open-label , multicenter , dose-escalation study evaluate safety , pharmacokinetics therapeutic activity RO6874281 participant advance and/or metastatic solid tumor . Participants treat disease progression unacceptable toxicity occur , maximum 24 month .</brief_summary>
	<brief_title>A Study Evaluating Safety , Pharmacokinetics , Therapeutic Activity RO6874281 Participants With Advanced and/or Metastatic Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Age great equal ( &gt; = ) 18 year Confirmed advance and/or metastatic solid tumor , least one tumor lesion location accessible biopsy per clinical judgment treat physician , confirmed progression baseline ; progress cancer therapy effective standard therapy exist Radiologically measurable clinically evaluable disease Life expectancy &gt; =12 week Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Adequate cardiovascular , hematological , liver renal function All acute toxic effect prior radiotherapy , chemotherapy , surgical procedure must resolve Grade le equal ( &lt; = ) 1 , except alopecia ( grade ) Grade 2 peripheral neuropathy Negative serum pregnancy test within 7 day prior study treatment premenopausal woman woman less ( &lt; ) 12 month menopause For woman postmenopausal undergone surgical sterilization : agreement remain abstinent use two adequate non hormonal method contraception , include least one method failure rate &lt; 1 percent ( % ) per year , treatment period least 4 month last dose study drug For men : agreement remain abstinent use contraceptive measure agreement refrain donate sperm treatment period least least 2 month last dose study drug Participants Gilbert 's syndrome eligible study History clinical evidence Central Nervous System ( CNS ) primary tumor metastases include leptomeningeal metastasis , unless previously treat , asymptomatic , requirement steroid enzyme induce anticonvulsant last 14 day prior screen Participants active second malignancy Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include diabetes mellitus , history relevant pulmonary disorder , know autoimmune disease disease ongoing fibrosis Significant cardiovascular/cerebrovascular disease within 6 month prior Day 1 study drug administration Active uncontrolled infection Known human immunodeficiency virus ( HIV ) know active hepatitis B virus hepatitis C virus infection History chronic liver disease evidence hepatic cirrhosis Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition would contraindicate use investigational drug Major surgery significant traumatic injury &lt; 28 day prior first RO6874281 infusion ( exclude biopsy ) anticipation need major surgery study treatment Dementia alter mental status would prohibit informed consent Pregnant breastfeeding woman Known hypersensitivity component RO6874281 Concurrent therapy investigational drug Immunomodulating agent &lt; 28 day prior first dose study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>